Neuroectoderm-derived tumors, sarcomas and embryonal tumors are hard to cure when they have metastasized. These cancers include neuroblastoma, retinoblastoma, melanoma, small cell lung cancer, brain tumors, osteosarcoma, rhabdomyosarcoma, Ewing’s sarcoma, liposarcoma, fibrosarcoma, leiomyosarcoma and other soft tissue sarcomas in adults. They have a common tumor antigen on their cell surface called disialoganglioside or GD2. Recently, numerous research laboratories have discovered that in addition, surface GD2 is present on breast cancer stem cells, neuroectodermal and mesenchymal stem cells.
Our humanized version of 3F8 has received Orphan Drug Status from the FDA in both neuroblastoma and osteosarcoma, and is currently in a Phase II clinical trial at MSK.